Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.

Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.

Item
http://www.wikidata.org/entity/Q44592465
Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapyFinding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it.Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinomaEpidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA ApprovalPrognostic biomarkers in patients with resected cholangiocarcinoma: a systematic review and meta-analysis.Differences in immunohistochemical biomarkers between intra- and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis.Potential biomarkers for sensitivity of gallbladder cancer cells to gemcitabineExpression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy.Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial.Predictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers.Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients.Astaxanthin inhibits gemcitabine-resistant human pancreatic cancer progression through EMT inhibition and gemcitabine resensitization.ERCC1 mRNA expression as a postoperative prognostic marker in extrahepatic bile duct cancer.
P2860

Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.

Item
http://www.wikidata.org/entity/Q44592465
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Excision repair cross-compleme ...... e in biliary tract malignancy.
@en
Excision repair cross-compleme ...... e in biliary tract malignancy.
@nl
type
label
Excision repair cross-compleme ...... e in biliary tract malignancy.
@en
Excision repair cross-compleme ...... e in biliary tract malignancy.
@nl
prefLabel
Excision repair cross-compleme ...... e in biliary tract malignancy.
@en
Excision repair cross-compleme ...... e in biliary tract malignancy.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
Excision repair cross-compleme ...... e in biliary tract malignancy.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698